Elevance Health, Inc 8-K, filed Oct 25, 2022
Elevance Health, Inc. (ELV)
About this 8-K
Elevance Health, Inc filed this 8-K on October 25, 2022, reporting on events of October 24, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 25, 2022 (
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 24, 2022, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Deanna Strable-Soethout to serve as an independent director effective November 1, 2022, with a term expiring at the Company’s 2023 annual meeting of shareholders. The Board also appointed Ms. Strable-Soethout to the Audit and Governance Committees of the Board. There is no arrangement or understanding between Ms. Strable-Soethout and any other person pursuant to which she was elected to the Board, and Ms. Strable-Soethout has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Ms. Strable-Soethout qualifies as an “audit committee financial expert” as defined in the Securities and Exchange Commission regulations.
Ms. Strable-Soethout will receive compensation for her services as a director in accordance with the Company’s standard compensation program for non-employee directors, which is filed as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
A copy of the Company’s press release announcing Ms. Strable-Soethout’s election is furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Exhibit | |
| 99.1 | Press Release, dated October 25, 2022, announcing the election of Deanna Strable-Soethout to the Elevance Health, Inc. Board of Directors. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 25, 2022
| ELEVANCE HEALTH, INC. | ||
| By: | /s/ Kathleen S. Kiefer | |
| Name: | Kathleen S. Kiefer | |
| Title: | Corporate Secretary | |
Exhibit 99.1
Elevance Health Board Welcomes Deanna Strable as New Director
INDIANAPOLIS – October 25, 2022 – The Board of Directors of Elevance Health (NYSE: ELV) announced that Deanna Strable will be joining the Board. She will serve on the Audit and Governance Committees.
With a career spanning more than three decades at a Fortune 500 global financial services company, Ms. Strable currently serves as the executive vice president and chief financial officer (CFO) for Principal Financial Group®. In her current position, she is responsible for the financial integrity and growth strategy of a Fortune 500 company, helping more than 50 million global customers make progress on their journey toward greater financial security.
Prior to her current role as CFO at Principal®, Ms. Strable served as president of the company’s U.S. Insurance Solutions division, with overall accountability for individual life insurance, nonqualified deferred compensation, individual disability insurance, and group benefits. As a strong promoter of inclusion at work and a champion for the growth and advancement of women, she is also the Co-founder and past Co-executive sponsor for the Women in Leadership network at Principal® and is credited with consistently developing high-caliber, diverse teams.
In addition, Ms. Strable serves on the board of directors for United Way Worldwide and previously, served as the past chair of the board of LIMRA LOMA Global, the world’s largest association of life insurance and financial services companies. She is a Fellow of the Society of Actuaries and a member of the American Academy of Actuaries.
“We are pleased to welcome Deanna to the Elevance Health Board of Directors. As a seasoned CFO with proven experience in the insurance industry, coupled with a demonstrated focus on diversity and culture, she will add valuable insights to the Board,” said Elizabeth Tallett, Chair, Elevance Health Board of Directors. “With Deanna’s addition, over 70% of our Board of Directors will be comprised of women and racially or ethnically diverse directors, and we continue to be the only Fortune 50 company with both a female CEO and female independent Board Chair.”
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.
Investor Relations:
Stephen Tanal
Stephen.Tanal@elevancehealth.com
Media Relations:
Leslie Porras
Leslie.Porras@elevancehealth.com